Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB-4746 in amyotrophic lateral sclerosis
NL-OMON61205Phase 2Recruiting
- Sponsor
- Nura Bio
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NB-4746 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Nura Bio. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Safety profile. Started Jun 2026; status: recruiting.
02
Drugs
NB-4746
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61205.